MUTIERTE IMMUNGLOBULINBINDENDE POLYPEPTIDE

European patent · EP3757123 · In force

Register entry

Publication number
EP3757123
Application number
EP20185632
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 16, 2015
Published
Dec 30, 2020
Granted
Aug 21, 2024
Protection ends at the latest
Nov 15, 2035
Next annual fee due
Nov 30, 2026
IPC classes
C07K 16/06 (2006.01)
C07K 1/22 (2006.01)
Priority
SE 1451376 17.11.2014
GB 201510261 12.06.2015
GB 201510263 12.06.2015
Divided from
EP15797940
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Dec 1, 2025

    Change

    Published in Swissreg on 01.12.2025

  2. Jul 2, 2025

    Change

    Published in Swissreg on 02.07.2025

  3. Dec 1, 2024

    Change

    Published in Swissreg on 01.12.2024

  4. Aug 27, 2024

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 27.08.2024

  5. Aug 21, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 21.08.2024

Parties

Holder

Cytiva BioProcess R&D AB

Björkgatan 30, 751 84 Uppsala, SE

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

RODRIGO, Gustav

751 84 Uppsala, SE

BJORKMAN, Tomas

751 84 Uppsala, SE

ANDER, Mats

751 84 Uppsala, SE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.